AU2012220702B2 - Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes - Google Patents

Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes Download PDF

Info

Publication number
AU2012220702B2
AU2012220702B2 AU2012220702A AU2012220702A AU2012220702B2 AU 2012220702 B2 AU2012220702 B2 AU 2012220702B2 AU 2012220702 A AU2012220702 A AU 2012220702A AU 2012220702 A AU2012220702 A AU 2012220702A AU 2012220702 B2 AU2012220702 B2 AU 2012220702B2
Authority
AU
Australia
Prior art keywords
tbx5
mef2c
gata4
hand2
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012220702A
Other languages
English (en)
Other versions
AU2012220702A1 (en
Inventor
Young-jae NAM
Eric Olson
Kunhua Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2012220702A1 publication Critical patent/AU2012220702A1/en
Application granted granted Critical
Publication of AU2012220702B2 publication Critical patent/AU2012220702B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012220702A 2011-02-22 2012-02-22 Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes Ceased AU2012220702B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161445390P 2011-02-22 2011-02-22
US61/445,390 2011-02-22
PCT/US2012/026113 WO2012116064A1 (en) 2011-02-22 2012-02-22 Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes

Publications (2)

Publication Number Publication Date
AU2012220702A1 AU2012220702A1 (en) 2013-08-22
AU2012220702B2 true AU2012220702B2 (en) 2016-12-15

Family

ID=45922797

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012220702A Ceased AU2012220702B2 (en) 2011-02-22 2012-02-22 Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes

Country Status (6)

Country Link
US (2) US9017661B2 (https=)
EP (1) EP2678354A1 (https=)
JP (1) JP2014507442A (https=)
AU (1) AU2012220702B2 (https=)
CA (1) CA2827329A1 (https=)
WO (1) WO2012116064A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2776071B1 (en) 2011-11-09 2018-08-08 Cedars-Sinai Medical Center Transcription factor-based generation of pacemaker cells and methods of using same
CA2934065C (en) * 2013-10-25 2023-05-09 Qurgen, Inc. Methods, systems and compositions relating to cell conversion via protein-induced in-vivo cell reprogramming
JP2015213441A (ja) * 2014-05-08 2015-12-03 学校法人慶應義塾 心筋様細胞の作製方法及びそれに用いる培地
WO2016022992A1 (en) * 2014-08-07 2016-02-11 Duke University Compositions and methods for the reprogramming of cells into cardiomyocytes
KR101530278B1 (ko) * 2014-09-04 2015-06-24 부산대학교 산학협력단 심근전환유전자 및 심혈관재생유전자를 포함하는 아데노부속바이러스를 유효성분으로 포함하는, 허혈성 심장질환 예방 또는 치료용 조성물
US9885018B1 (en) 2015-03-16 2018-02-06 The Regents Of The University Of Colorado, A Body Corporate High efficiency reprogramming of fibroblasts into cardiomyocytes
US20200216813A1 (en) * 2017-06-21 2020-07-09 Mogrify Limited Cell reprogramming to cardiomyocytes
WO2019036086A1 (en) * 2017-08-15 2019-02-21 The Board Of Regents Of The University Of Texas System CARDIAC REPAIR BY REPROGRAMMING CARDIAC FIBROBLASTS ADULT TO CARDIOMYOCYTES
US12042525B2 (en) 2018-01-05 2024-07-23 University Of Houston System Serum response factor regenerates senescent cells
GB2571704A (en) * 2018-02-22 2019-09-11 Georg August Univ Gottingen Stiftung Offentlichen Rechts Univer Sitatsmedzin Goettingen Prevention or treatment of cardiac arrhytmia and sudden cardiac death
JP7450945B2 (ja) 2018-08-30 2024-03-18 テナヤ セラピューティクス， インコーポレイテッド ミオカルディンおよびａｓｃｌ１を用いた心細胞リプログラミング

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008088882A2 (en) * 2007-01-19 2008-07-24 The J. David Gladstone Institutes Methods of generating cardiomyocytes
WO2011139688A2 (en) * 2010-04-28 2011-11-10 The J. David Gladstone Institutes Methods for generating cardiomyocytes
WO2011163531A2 (en) * 2010-06-23 2011-12-29 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
EP1085910A2 (en) * 1998-05-30 2001-03-28 Collateral Therapeutics, Inc. Methods of altering cardiac cell phenotype
WO2002002148A2 (en) * 2000-06-30 2002-01-10 Collateral Therapeutics, Inc. Dual recombinant gene therapy compositions and methods of use
WO2007056759A2 (en) * 2005-11-08 2007-05-18 University Of South Florida Improved method of stem cell therapy for cardiovascular repair
WO2009145761A1 (en) * 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Methods and materials for using cells to treat heart tissue
EP2641911A3 (en) * 2008-12-23 2014-01-01 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008088882A2 (en) * 2007-01-19 2008-07-24 The J. David Gladstone Institutes Methods of generating cardiomyocytes
WO2011139688A2 (en) * 2010-04-28 2011-11-10 The J. David Gladstone Institutes Methods for generating cardiomyocytes
WO2011163531A2 (en) * 2010-06-23 2011-12-29 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IEDA et al. "Direct Reprogramming of Fibroblasts into Functional Cardiomyocytes by Defined Factors", 2010, Cell, Vol. 142, Pages 375-386. *

Also Published As

Publication number Publication date
US20120213738A1 (en) 2012-08-23
CA2827329A1 (en) 2012-08-30
US9523079B2 (en) 2016-12-20
US9017661B2 (en) 2015-04-28
EP2678354A1 (en) 2014-01-01
WO2012116064A1 (en) 2012-08-30
AU2012220702A1 (en) 2013-08-22
US20150307847A1 (en) 2015-10-29
JP2014507442A (ja) 2014-03-27

Similar Documents

Publication Publication Date Title
AU2012220702B2 (en) Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes
US20200190511A1 (en) Micro-rna family that modulates fibrosis and uses thereof
US20050182011A1 (en) Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure
US10300147B2 (en) Therapeutic miRNAs for treating heart and skeletal muscle diseases
US20250018009A1 (en) Serum response factor regenerates senescent cells
AU2004249114A1 (en) Inhibition of protein kinase C-mu (PKD) as a treatment for cardiac hypertrophy and heart failure
WO2019036086A1 (en) CARDIAC REPAIR BY REPROGRAMMING CARDIAC FIBROBLASTS ADULT TO CARDIOMYOCYTES
WO2007131113A2 (en) Modulation of calmodulin- binding transcription activator (camta) as a treatment for cardiac hypertrophy, heart failure, and heart injury
US20090220507A1 (en) Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure
US20050265999A1 (en) Modulation of 5-HT2 receptors as a treatment for cardiovascular diseases
US20050283841A1 (en) Inhibition of protein kinase C-related kinase (PRK) as a treatment for cardiac hypertrophy and heart failure
US20080031818A1 (en) Use of Modulators of a Novel Form of Muscle Selective Calcineurin Interacting Protein (Mcip-1-38) as a Treatment for Cardiovascular Diseases
US20060110390A1 (en) Inhibition of Ku as a treatment for cardiovascular diseases
WO2023077052A1 (en) Reprogramming of adult cardiac fibroblasts into cardiomyocytes using phf7
US20050288215A1 (en) Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
AU2016266042A1 (en) A micro-rna family that modulates fibrosis and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired